International Stem Cell (ISCO) Stock Price

International Stem Cell Price

OTC·CLOSED
0.27USD+0.01 (+3.77 %)
Market closed

Over the last 18 years International Stem Cell grew revenue by 35.2% annually, reaching 9.10 M USD. For International Stem Cell, the net margin of -4.6% is up versus -12.5% a few years ago. The stock trades about 125% above its 52-week low.

International Stem Cell stock price

Volume
Details

Stock Price

ⓘ

How to Read This Chart

This chart tracks the historical stock price of International Stem Cell over time. You can switch between daily, weekly, and monthly views and select custom time ranges — from a single day to the full available history. Use the toggle to view price changes in absolute currency terms or as a percentage change relative to the starting date.

Total Return vs. Price Return

The "Total Return" toggle includes reinvested dividends on top of the pure price movement. This is critical because dividends can account for a significant portion of long-term returns. Historically, roughly 40 % of the S&P 500's total return has come from dividends. Always compare total return when evaluating a stock's real performance against a benchmark.

Intraday Price Data

When viewing a one-day time frame, the chart displays real-time intraday price movements. This is useful for observing how International Stem Cell stock reacts to market openings, earnings releases, or breaking news throughout the trading session.

What to Look For

Look for long-term trends (sustained upward or downward movements over months and years), support and resistance levels (price zones where the stock repeatedly bounces or reverses), and volatility (how much the price fluctuates day to day). Comparing International Stem Cell's price chart to a market index like the S&P 500 can reveal whether the stock is outperforming or underperforming the broader market.

International Stem Cell Stock Price History
DateInternational Stem Cell Price
7/31/20260.27 USD
7/30/20260.26 USD
7/29/20260.29 USD
7/28/20260.29 USD
7/27/20260.28 USD
7/23/20260.28 USD
7/22/20260.17 USD
7/21/20260.17 USD
7/20/20260.20 USD
7/17/20260.18 USD
7/16/20260.21 USD
7/15/20260.17 USD
7/14/20260.17 USD
7/13/20260.17 USD
7/10/20260.17 USD
7/9/20260.16 USD
7/8/20260.16 USD
7/7/20260.17 USD
7/6/20260.17 USD
7/2/20260.20 USD
7/1/20260.18 USD
6/30/20260.19 USD
6/29/20260.18 USD
6/26/20260.18 USD
6/25/20260.19 USD
6/24/20260.18 USD
6/23/20260.17 USD
6/22/20260.17 USD
6/18/20260.17 USD
6/17/20260.17 USD
6/16/20260.17 USD
6/15/20260.17 USD
6/12/20260.17 USD
6/11/20260.17 USD
6/10/20260.17 USD
6/9/20260.18 USD
6/8/20260.18 USD
6/5/20260.18 USD
6/4/20260.18 USD
6/3/20260.18 USD
6/2/20260.17 USD
6/1/20260.17 USD
5/29/20260.17 USD
5/28/20260.17 USD
5/27/20260.17 USD
5/26/20260.17 USD
5/22/20260.17 USD
5/21/20260.17 USD
5/20/20260.18 USD
5/19/20260.18 USD
5/18/20260.18 USD
5/15/20260.18 USD
5/14/20260.18 USD
5/13/20260.18 USD
5/12/20260.17 USD
5/11/20260.17 USD
5/8/20260.17 USD
5/7/20260.17 USD
5/6/20260.18 USD
5/5/20260.18 USD
5/1/20260.19 USD
4/30/20260.16 USD
4/28/20260.17 USD
4/27/20260.15 USD
4/22/20260.14 USD
4/17/20260.18 USD
4/16/20260.18 USD
4/15/20260.15 USD
4/7/20260.14 USD
3/31/20260.17 USD
3/30/20260.16 USD
3/27/20260.17 USD
3/26/20260.16 USD
3/25/20260.14 USD
3/24/20260.14 USD
3/20/20260.14 USD
3/19/20260.14 USD
3/16/20260.15 USD
3/13/20260.18 USD
3/10/20260.17 USD
3/9/20260.18 USD
3/4/20260.14 USD
3/3/20260.14 USD
2/27/20260.14 USD
2/26/20260.15 USD
2/24/20260.14 USD
2/23/20260.14 USD
2/20/20260.15 USD
2/18/20260.17 USD
2/13/20260.18 USD
2/5/20260.17 USD
2/4/20260.18 USD
2/3/20260.14 USD
2/2/20260.16 USD
1/30/20260.14 USD
1/29/20260.16 USD
1/28/20260.17 USD
1/27/20260.17 USD
1/26/20260.15 USD
1/23/20260.16 USD
1/22/20260.16 USD
1/21/20260.16 USD
1/20/20260.16 USD
1/15/20260.13 USD
1/14/20260.13 USD
1/12/20260.12 USD
1/8/20260.13 USD
12/31/20250.14 USD
12/30/20250.14 USD
12/29/20250.12 USD
12/26/20250.14 USD
12/24/20250.13 USD
12/23/20250.13 USD
12/22/20250.14 USD
12/19/20250.14 USD
12/16/20250.14 USD
12/11/20250.17 USD
12/10/20250.14 USD
12/8/20250.14 USD
12/5/20250.14 USD
12/2/20250.14 USD
12/1/20250.14 USD
11/28/20250.15 USD
11/26/20250.14 USD
11/25/20250.17 USD
11/24/20250.15 USD
11/21/20250.15 USD
11/20/20250.15 USD
11/18/20250.15 USD
11/14/20250.15 USD
11/10/20250.16 USD
11/6/20250.14 USD
11/4/20250.15 USD
10/30/20250.15 USD
10/28/20250.15 USD
10/27/20250.15 USD
10/22/20250.15 USD
10/21/20250.15 USD
10/20/20250.15 USD
10/17/20250.15 USD
10/16/20250.19 USD
10/15/20250.17 USD
10/14/20250.15 USD
10/13/20250.15 USD
10/10/20250.13 USD
10/7/20250.14 USD
10/6/20250.14 USD
9/29/20250.13 USD
9/25/20250.13 USD
9/24/20250.13 USD
9/22/20250.13 USD
9/18/20250.14 USD
9/16/20250.13 USD
9/12/20250.13 USD
9/3/20250.14 USD
8/29/20250.13 USD
8/28/20250.13 USD
8/27/20250.14 USD
8/26/20250.12 USD
8/25/20250.15 USD
8/21/20250.15 USD
8/19/20250.16 USD
8/18/20250.18 USD
8/14/20250.15 USD
8/13/20250.15 USD
8/12/20250.16 USD
8/11/20250.17 USD
Access this data via the Eulerpool API
Get Free API Key

International Stem Cell Revenue, EBIT, Net Income

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details
Date
Revenue
EBIT
Net Income
Jan 1, 2022
8.18 M USD
-196,000.00 USD
-331,000.00 USD
Jan 1, 2023
7.79 M USD
-663,000.00 USD
-131,000.00 USD
Jan 1, 2024
9.09 M USD
-68,000.00 USD
-209,000.00 USD
Jan 1, 2025
9.10 M USD
-267,000.00 USD
-418,000.00 USD
Jan 1, 2026 (e)
7.32 M USD
432,190.00 USD
-5.76 M USD
Jan 1, 2027 (e)
11.46 M USD
676,936.00 USD
-2.56 M USD
Jan 1, 2028 (e)
9.89 M USD
584,248.00 USD
-4.32 M USD
Jan 1, 2029 (e)
10.69 M USD
631,331.00 USD
-9.29 M USD

International Stem Cell Income Statement, Balance Sheet, Cash Flow Statement

Last updated Aug 4, 2026, 7:27 PM
 
REVENUEM USD
REVENUE GROWTH%
GROSS MARGIN%
GROSS INCOMEM USD
EBITM USD
EBIT MARGIN%
NET INCOMEM USD
NET INCOME GROWTH%
SHARESk
2014201520162017201820192020202120222023202420252026e2027e2028e2029e
7.007.007.007.0011.009.007.007.008.007.009.009.007.0011.009.0010.00
16.67–––57.14-18.18-22.22–14.29-12.5028.57–-22.2257.14-18.1811.11
71.4371.4371.4371.4363.6455.5657.1457.1450.0057.1455.5655.5655.5655.5655.5655.56
5.005.005.005.007.005.004.004.004.004.005.005.003.896.115.005.56
-8.00-4.00-4.00-6.00-3.00-5.00-2.00-1.00––––––––
-114.29-57.14-57.14-85.71-27.27-55.56-28.57-14.29––––––––
-12.00-2.00-1.00-6.00-2.00-4.00-2.00–––––-5.00-2.00-4.00-9.00
20.00-83.33-50.00500.00-66.67100.00-50.00––––––-60.00100.00125.00
510.00510.00510.00510.00510.00510.00510.00510.00510.00510.00510.00510.00510.00510.00510.00510.00
Details

Income Statement Key Figures

ⓘ

Revenue and Revenue Growth

Revenue is the starting point of every income statement — it measures the total sales International Stem Cell generates from its core business. Revenue growth (expressed as year-over-year percentage change) is one of the most important indicators of business momentum. Sustained growth above 10 % annually is generally considered strong, while declining revenue is a serious warning sign that demands investigation.

Gross Margin

Gross margin = (Revenue − Cost of Goods Sold) ÷ Revenue. It reveals what percentage of each dollar of revenue International Stem Cell retains after direct production costs. High gross margins (above 50 %) are typical of asset-light businesses like software and brands, while capital-intensive industries like manufacturing often operate below 30 %. Compare International Stem Cell's gross margin to industry peers and track it over time to spot improving or deteriorating pricing power.

EBIT and EBIT Margin

EBIT measures operating profit — what remains after subtracting all operating expenses (including R&D, sales, and administrative costs) from gross profit. The EBIT margin shows this as a percentage of revenue. Because it excludes interest and taxes, EBIT allows fair comparisons between companies with different debt levels and tax jurisdictions. A rising EBIT margin indicates improving operational efficiency.

Net Income and Earnings Per Share (EPS)

Net income is the company's final profit after all expenses, interest, and taxes. Dividing net income by the number of shares outstanding gives you EPS — the single most influential metric in stock valuation. Consistent EPS growth is the primary driver of long-term stock price appreciation. Always check whether EPS growth comes from genuine profit improvement or from share buybacks reducing the share count.

Shares Outstanding

The total number of shares International Stem Cell has issued. A declining share count (through buybacks) boosts EPS and signals management confidence. A rising share count (through stock issuance) dilutes existing shareholders. Always monitor this number alongside EPS to get the full picture of per-share value creation.

Analyst Estimates

The projected figures represent consensus estimates from professional analysts. Compare these forecasts against International Stem Cell's historical growth rates to assess whether expectations are realistic. A company that consistently beats consensus estimates tends to see its stock price rewarded over time, while repeated misses erode investor confidence.

International Stem Cell stock margins

The International Stem Cell margin analysis displays the gross margin, EBIT margin, as well as the profit margin of International Stem Cell. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for International Stem Cell.

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details
Date
Gross margin
EBIT margin
Profit margin
Jan 1, 2021
59.10 %
-23.29 %
-12.53 %
Jan 1, 2022
60.04 %
-2.40 %
-4.05 %
Jan 1, 2023
59.16 %
-8.51 %
-1.68 %
Jan 1, 2024
58.57 %
-0.75 %
-2.30 %
Jan 1, 2025
55.68 %
-2.93 %
-4.59 %
Jan 1, 2026 (e)
55.68 %
5.91 %
-78.77 %
Jan 1, 2027 (e)
55.68 %
5.91 %
-22.35 %
Jan 1, 2028 (e)
55.68 %
5.91 %
-43.70 %

International Stem Cell Stock Revenue, EBIT, Earnings per Share

The International Stem Cell earnings per share therefore indicates how much revenue International Stem Cell has generated per share in a given period. The earnings before interest and taxes per share shows how much of the operating profit corresponds to each share. The earnings per share indicates how much of the profit belongs to each share.

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Revenue per Share
EBIT per share
Earnings per Share
Details
Date
Revenue per Share
EBIT per share
Earnings per Share
Jan 1, 2021
0.00 USD
0.00 USD
0.00 USD
Jan 1, 2022
0.00 USD
0.00 USD
0.00 USD
Jan 1, 2023
0.00 USD
0.00 USD
0.00 USD
Jan 1, 2024
0.00 USD
0.00 USD
0.00 USD
Jan 1, 2025
0.00 USD
0.00 USD
0.00 USD
Jan 1, 2026 (e)
0.91 USD
0.85 USD
-0.72 USD
Jan 1, 2027 (e)
1.43 USD
1.33 USD
-0.32 USD
Jan 1, 2028 (e)
1.24 USD
1.15 USD
-0.54 USD

International Stem Cell business model & stock analysis

International Stem Cell Corp (ISCO) is a biotechnology company founded in 2005 and headquartered in Carlsbad, California. It specializes in the development and manufacture of stem cell products for therapeutics and research purposes. ISCO specializes in the production of "human parthenogenetic stem cells" (hpSCs). This means that they produce stem cells from human egg cells that can replicate without fertilization by sperm. The company is a leader in this field and has filed over 80 patents worldwide. ISCO has various business areas, including life science research, therapeutics, dermatology, and animal health. The company partners with various industries, including academic institutions, pharmaceutical and biotechnology companies, and government agencies. One of their biggest partnerships is with the Chinese company Sino Biopharmaceuticals. ISCO offers a variety of products, including in vitro diagnostics for testing genetic diseases such as Huntington's and food allergies. However, the diagnostics division of the company is a small department primarily focused on research and development purposes. ISCO also has a dermatology division called Lifeline Skin Care, which manufactures skincare products based on human stem cells. These products have been developed for improving skin texture and reducing scars. Lifeline Skin Care is a luxury brand for skincare products currently sold in over 15 countries worldwide. In terms of animal health, ISCO recently launched a new division called Lifeline Animal Health. They are developing animal therapeutics based on hpSCs. The company has already developed the first animal therapeutic for dogs approved for the treatment of hip dysplasia. However, ISCO primarily focuses on the development of therapeutics for human stem cells. The company aims to be a global leader in the development of stem cell therapeutics. Their first product, CytoCor for heart disease, is already in clinical phase 1b/2a. The drug is intended to help reduce damage after a heart attack and improve heart function. ISCO also plans to develop therapeutics for other indications, including Alzheimer's disease, based on hpSCs. The company has a strong partnership with the California Institute for Regenerative Medicine, which focuses on stem cell research and their use in medicine. ISCO is a leading company in stem cell research and development. They have a unique approach to stem cell production and offer a variety of products and services for various industries. The company aims to develop groundbreaking stem cell therapeutics and change the way diseases are treated.

International Stem Cell SWOT Analysis

Strengths

  • International Stem Cell Corp has a strong research and development team consisting of experienced scientists and clinicians.
  • The company possesses proprietary technologies and intellectual property related to stem cell-based therapies.
  • International Stem Cell Corp has a diversified product portfolio, including therapies for neurological disorders and cosmetic applications.

Weaknesses

  • The company faces regulatory challenges and restrictions in some countries that limit the commercialization of their products.
  • International Stem Cell Corp may experience difficulties in obtaining necessary funding for research and development activities.
  • The company's dependence on third-party suppliers for raw materials and technology components poses a risk to the supply chain.

Opportunities

  • The increasing prevalence of chronic diseases and the aging population present a growing market for stem cell therapies.
  • International Stem Cell Corp could expand its market reach by establishing strategic partnerships with healthcare organizations and biotechnology companies.
  • Emerging markets offer untapped potential for the company's stem cell-based products and treatments.

Threats

  • Competition in the stem cell industry is intensifying with the entry of new players, which may impact market share and pricing.
  • Legal and ethical concerns surrounding the use of stem cells could result in stricter regulations and public backlash.
  • Economic downturns and financial instability may reduce funding opportunities for research and development.

International Stem Cell Employees

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

International Stem Cell Employees
Details
Date
International Stem Cell Employees
Jan 1, 2018
- Employees
Jan 1, 2019
- Employees
Jan 1, 2020
- Employees
Jan 1, 2021
- Employees
Jan 1, 2022
- Employees
Jan 1, 2023
- Employees
Jan 1, 2024
- Employees
Jan 1, 2025
- Employees

International Stem Cell Segments

International Stem Cell Revenue by Segment (1/5)

  • 3 Years

  • 5 Years

  • Max

Product
Media
Cells
Ecommerce
Lower limit of the provided range
Other biomedical products
Clinical
Therapeutic
Details
Date
Product
Media
Cells
Ecommerce
Lower limit of the provided range
Other biomedical products
Clinical
Therapeutic
Jan 1, 2016
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
Jan 1, 2017
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
Jan 1, 2018
11.09 M USD
7.34 M USD
1.00 M USD
976,000.00 USD
836,000.00 USD
18,000.00 USD
0.00 USD
0.00 USD
Jan 1, 2019
0.00 USD
6.23 M USD
1.25 M USD
0.00 USD
0.00 USD
20,000.00 USD
0.00 USD
0.00 USD
Jan 1, 2020
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
Jan 1, 2021
0.00 USD
4.59 M USD
1.35 M USD
913,000.00 USD
327,000.00 USD
0.00 USD
0.00 USD
0.00 USD
Jan 1, 2022
0.00 USD
5.19 M USD
1.94 M USD
1.05 M USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
Jan 1, 2024
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD

International Stem Cell Revenue by Segment (2/5)

  • Max

Media
Cells
Details
Date
Media
Cells
Jan 1, 2016
0.00 USD
0.00 USD
Jan 1, 2017
0.00 USD
0.00 USD
Jan 1, 2018
0.00 USD
0.00 USD
Jan 1, 2019
0.00 USD
0.00 USD
Jan 1, 2020
0.00 USD
0.00 USD
Jan 1, 2021
0.00 USD
0.00 USD
Jan 1, 2022
0.00 USD
0.00 USD
Jan 1, 2024
5.95 M USD
2.34 M USD

International Stem Cell Revenue by Segment (3/5)

  • 3 Years

  • 5 Years

  • Max

Biomedical market
Cosmetic market
Anti Aging Skincare Market
Anti aging market
Anti-Aging Skincare Market
Details
Date
Biomedical market
Cosmetic market
Anti Aging Skincare Market
Anti aging market
Anti-Aging Skincare Market
Jan 1, 2016
0.00 USD
2.85 M USD
0.00 USD
0.00 USD
0.00 USD
Jan 1, 2017
0.00 USD
2.26 M USD
0.00 USD
0.00 USD
0.00 USD
Jan 1, 2018
1.00 M USD
976,000.00 USD
0.00 USD
0.00 USD
0.00 USD
Jan 1, 2019
7.50 M USD
1.97 M USD
0.00 USD
0.00 USD
0.00 USD
Jan 1, 2020
0.00 USD
0.00 USD
0.00 USD
1.53 M USD
0.00 USD
Jan 1, 2021
0.00 USD
0.00 USD
1.24 M USD
0.00 USD
0.00 USD
Jan 1, 2022
0.00 USD
0.00 USD
0.00 USD
0.00 USD
1.05 M USD
Jan 1, 2024
0.00 USD
0.00 USD
0.00 USD
0.00 USD
795,000.00 USD

International Stem Cell Revenue by Segment (4/5)

  • 3 Years

  • 5 Years

  • Max

Biomedical Market
Anti Aging Skincare Market
Details
Date
Biomedical Market
Anti Aging Skincare Market
Jan 1, 2016
4.32 M USD
0.00 USD
Jan 1, 2017
5.20 M USD
0.00 USD
Jan 1, 2018
0.00 USD
0.00 USD
Jan 1, 2019
0.00 USD
0.00 USD
Jan 1, 2020
5.59 M USD
1.53 M USD
Jan 1, 2021
5.94 M USD
0.00 USD
Jan 1, 2022
7.13 M USD
0.00 USD
Jan 1, 2024
8.29 M USD
0.00 USD

International Stem Cell Revenue by Segment (5/5)

  • 3 Years

  • Max

Anti aging market
Anti-aging Market
Details
Date
Anti aging market
Anti-aging Market
Jan 1, 2016
0.00 USD
0.00 USD
Jan 1, 2017
0.00 USD
0.00 USD
Jan 1, 2018
0.00 USD
0.00 USD
Jan 1, 2019
0.00 USD
0.00 USD
Jan 1, 2020
0.00 USD
0.00 USD
Jan 1, 2021
1.24 M USD
0.00 USD
Jan 1, 2022
0.00 USD
1.05 M USD
Jan 1, 2024
0.00 USD
795,000.00 USD

International Stem Cell Revenue by Region

  • 3 Years

  • 5 Years

  • Max

United States
North America
International
Asia
OUS
Europe
All Other Regions
Other regions
Details
Date
United States
North America
International
Asia
OUS
Europe
All Other Regions
Other regions
Jan 1, 2016
0.00 USD
6.06 M USD
0.00 USD
702,000.00 USD
0.00 USD
362,000.00 USD
0.00 USD
40,000.00 USD
Jan 1, 2017
0.00 USD
6.35 M USD
0.00 USD
728,000.00 USD
0.00 USD
354,000.00 USD
0.00 USD
27,000.00 USD
Jan 1, 2018
1.00 M USD
10.16 M USD
0.00 USD
612,000.00 USD
405,000.00 USD
293,000.00 USD
0.00 USD
24,000.00 USD
Jan 1, 2019
6.62 M USD
8.58 M USD
0.00 USD
540,000.00 USD
878,000.00 USD
325,000.00 USD
0.00 USD
24,000.00 USD
Jan 1, 2020
0.00 USD
6.28 M USD
0.00 USD
538,000.00 USD
0.00 USD
290,000.00 USD
0.00 USD
23,000.00 USD
Jan 1, 2021
4.74 M USD
5.98 M USD
1.20 M USD
806,000.00 USD
0.00 USD
345,000.00 USD
0.00 USD
45,000.00 USD
Jan 1, 2022
7.02 M USD
0.00 USD
1.12 M USD
690,000.00 USD
0.00 USD
393,000.00 USD
81,000.00 USD
0.00 USD
Jan 1, 2024
7.73 M USD
0.00 USD
1.33 M USD
890,000.00 USD
0.00 USD
407,000.00 USD
61,000.00 USD
0.00 USD

International Stem Cell Eulerpool Fair Value

Details

Fair Value Estimate

ⓘ

What Is Fair Value?

Fair value is an estimate of what a stock is truly "worth" based on its financial fundamentals, independent of the current market price. If the calculated fair value is above the current share price, the stock may be undervalued — and vice versa. This chart shows three different fair value approaches so you can cross-check them against each other.

Earnings-Based Fair Value

Calculated by multiplying the current earnings per share (EPS) by the average historical P/E ratio over a selected multi-year period. The smoothing over several years filters out temporary spikes or dips. If this fair value exceeds the market price, it suggests the stock is cheap relative to its earning power.

Example: Fair Value (Earnings) 2022 = EPS 2022 × Average P/E 2019–2021

Revenue-Based Fair Value

Derived by multiplying revenue per share by the average historical price-to-sales ratio. This method is particularly useful for companies with volatile or temporarily depressed earnings, as revenue tends to be more stable than profits. It answers: "At what price has the market historically valued each dollar of this company's sales?"

Example: Fair Value (Revenue) 2022 = Revenue per Share 2022 × Average P/S 2019–2021

Dividend-Based Fair Value

Calculated by dividing the dividend per share by the average historical dividend yield. This approach is most relevant for mature, consistently dividend-paying companies. If the resulting fair value is higher than the current price, it implies the stock offers a better yield than its historical average.

Example: Fair Value (Dividend) 2022 = Dividend per Share 2022 ÷ Average Yield 2019–2021

How to Use This Chart

When all three fair value lines converge above the current price, it strengthens the case that the stock is undervalued. When they diverge, investigate why — it may indicate a structural shift in margins, payout policy, or growth rate. The forward estimates on the right extend the analysis using projected fundamentals, helping you assess whether the current price already reflects future growth expectations.

International Stem Cell historical P/E ratio, EBIT multiple, and P/S ratio

International Stem Cell annual returns

Details

Annual Return

ⓘ

What This Chart Shows

This chart breaks down 's total annual return into two components: price return (gains or losses from stock price movement) and dividend return (income received from dividend payments). Together, they represent the total return an investor would have earned in each calendar year.

Price Return

Price return measures the percentage change in 's stock price from January 1st to December 31st of each year. Positive bars indicate the stock appreciated; negative bars show a decline. This is the component most investors focus on, but it tells only part of the story — especially for dividend-paying stocks.

Dividend Return

Dividend return represents the income generated from dividends paid during the year, expressed as a percentage of the starting stock price. While it may seem small in any single year (typically 1–4 % for established companies), dividends compound significantly over decades and have historically contributed roughly 40 % of total stock market returns.

What to Look For

Examine how many years showed positive vs. negative returns to gauge consistency. A stock with mostly positive years and small drawdowns suggests lower risk. Also compare 's annual returns to a benchmark index — consistently outperforming the market is a hallmark of a strong investment. Pay attention to the worst years: understanding downside risk is just as important as chasing upside potential.

International Stem Cell shares outstanding

The number of shares of International Stem Cell was 510,000 in 2025. This indicates how many shares International Stem Cell is divided into. Since shareholders are the owners of a company, each share represents a small portion of the company's ownership.

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Number of stocks
Details
Date
Number of stocks
Jan 1, 2021
510,000.00 Stocks
Jan 1, 2022
510,000.00 Stocks
Jan 1, 2023
510,000.00 Stocks
Jan 1, 2024
510,000.00 Stocks
Jan 1, 2025
510,000.00 Stocks
Jan 1, 2026 (e)
510,000.00 Stocks
Jan 1, 2027 (e)
510,000.00 Stocks
Jan 1, 2028 (e)
510,000.00 Stocks

International Stem Cell stock splits

In International Stem Cell's history, there have been no stock splits.
Price targets and forecasts for International Stem Cell are not yet available.

International Stem Cell Earnings Estimates & Surprises

DateEPS estimateEPS ActualRevenue EstimatePrice reactionQuarterly report
11/13/2014-1.53USD-1.93 MUSD-2014 Q3
8/8/2014-1.53USD-1.88 MUSD-2014 Q2

International Stem Cell shareholder structure

% Name
51.07101%
Semechkin Andrey
Semechkin Andrey
2.22875%
Kern (Russell)
Kern (Russell)
0.40980%
Maier (Paul V)
Maier (Paul V)
0.05920%
Wright (Donald A)
Wright (Donald A)

International Stem Cell Beneficial Ownership Filings (SEC 13D/G)

Free Float
46.2%
Float Shares
-
Shares Outstanding
-
StakeHolderFiling
82.10%
X-Master, Inc.
X-Master, Inc.
SEC ↗
82.10%
Russell Kern
Russell Kern
SEC ↗
82.10%
AR Partners, LLC
AR Partners, LLC
SEC ↗
82.10%
Andrey Semechkin
Andrey Semechkin
SEC ↗
55.40%
Ruslan Semechkin
Ruslan Semechkin
SEC ↗
27.50%
Rouslan Semechkin
Rouslan Semechkin
SEC ↗
27.50%
Andrei Semechkin
Andrei Semechkin
SEC ↗
11.77%
Kenneth C. Aldrich (personally and on behalf of YKA Partners, Ltd., whose shares are beneficially he
Kenneth C. Aldrich (personally and on behalf of YKA Partners, Ltd., whose shares are beneficially he
SEC ↗
11.24%
Kenneth C. Aldrich
Kenneth C. Aldrich
SEC ↗
9.90%
Terren S. Peizer
Terren S. Peizer
SEC ↗

International Stem Cell Executives and Management Board

4 members · avg. age 64 · 0 % women

RK

Dr. Russell Kern (39)

Principal Financial Officer, Executive Vice President, Chief Scientific Officer, Director · since 2008

260,000.00 USD

Management

DW

Mr. Donald Wright (73)

Independent Co-Chairman of the Board, CEO and President of SIS, Inc.

71,822.00 USD
AS

Dr. Andrey Semechkin (65)

Co-Chairman of the Board, Chief Executive Officer

66,480.00 USD

Board of Directors

PM

Mr. Paul Maier (77)

Independent Director

56,822.00 USD

Frequently asked questions about International Stem Cell

The business model of International Stem Cell Corp focuses on the development and commercialization of stem cell-based therapies and biomedical products. Through its innovative platform technologies, the company aims to address various medical conditions and improve patient outcomes. International Stem Cell Corp leverages its expertise in stem cell research to develop proprietary cell therapy products, including neural stem cells for the treatment of Parkinson's disease and human parthenogenetic stem cells for applications in regenerative medicine. By integrating advanced scientific knowledge and strategic collaborations, the company strives to provide cutting-edge solutions in the field of stem cell science and contribute to the advancement of medical treatments.

International Stem Cell Corp is primarily active in the field of regenerative medicine, focusing on developing and commercializing cell-based therapeutics and biomedical products. With a strong emphasis on stem cell research, the company leverages its proprietary technologies to explore potential applications in various industries such as pharmaceuticals, cosmetics, and research tools. By harnessing the therapeutic potential of stem cells, International Stem Cell Corp aims to revolutionize and improve treatments for a wide range of medical conditions.

The main competitors of International Stem Cell Corp in the market are [competitor names].

International Stem Cell Corp (ISCO) is a renowned biotechnology company with a rich and influential history. Founded in 2001, ISCO specializes in the development and commercialization of novel stem cell-based therapies and biomedical products. With a global presence, the company has made significant breakthroughs in the field of regenerative medicine. ISCO is committed to revolutionizing healthcare by utilizing its proprietary technologies, such as parthenogenesis, to generate pluripotent stem cells. These cells have immense potential for various applications, including treating diseases and disorders. Over the years, International Stem Cell Corp has garnered a strong reputation and remains dedicated to advancing the frontiers of stem cell research, ultimately aiming to improve patients' lives worldwide.

International Stem Cell Corp has achieved several significant milestones in its journey. These include the successful development and commercialization of breakthrough technologies in the field of regenerative medicine. The company has made notable advancements in the use of human parthenogenetic stem cells, producing a potentially unlimited source of cells for research and therapeutic purposes. International Stem Cell Corp has also successfully transformed these cells into various specialized cell types, opening doors to numerous therapeutic applications. With its innovative research and development initiatives, the company continues to pave the way for the advancement of regenerative medicine and holds promising potential for addressing unmet medical needs.

International Stem Cell Corp is primarily present in several countries and regions worldwide. The company has a significant presence in the United States, where it is headquartered and operates its main research and development activities. Additionally, International Stem Cell Corp has a strong presence in major international markets such as Australia, Canada, and the United Kingdom. Through strategic partnerships and collaborations, the company has expanded its reach and operations to other regions, including Europe, Asia, and South America. International Stem Cell Corp's global footprint allows it to leverage diverse markets and access various resources to fulfill its mission in advancing innovative stem cell technologies and therapies.

International Stem Cell Corp represents a strong commitment to advancing regenerative medicine and developing novel therapies using stem cells. The company focuses on harnessing the potential of human parthenogenetic stem cells (hpSCs) to address unmet medical needs. With a dedication to scientific innovation and ethical practices, International Stem Cell Corp aims to provide safe and effective solutions for patients worldwide. Emphasizing rigorous research and development, the company strives to improve the quality of life through the application of cutting-edge stem cell technologies. Their corporate philosophy revolves around delivering groundbreaking treatments while maintaining transparency, integrity, and patient-centricity.

Converted at the current exchange rate, the International Stem Cell share trades at 0.23 EUR (0.27 USD).

The International Stem Cell Corp (ISCO) is a biotechnology company specializing in the research and development of stem cell therapies. The company operates in multiple divisions and offers a variety of products and services. ISCO has its own technology platform that allows for the extraction and cultivation of stem cells from human tissue. The technology allows for the production of stem cells without any alterations, making them suitable for medical use. One of the company's divisions focuses on the development of stem cell therapies. ISCO is working on therapies for a range of diseases and injuries. The company has already made successful progress in developing therapy approaches for Type 1 diabetes and aims to achieve breakthroughs in other medications. Another business area for ISCO is the manufacturing of cell products and services. The company offers both cell products and cell manufacturing services, enabling other companies to produce their own products based on stem cells. ISCO has its own production facilities in California and Singapore. Additionally, ISCO operates a veterinary medicine division, which focuses on developing stem cell therapies for pets. The company researches therapies for various animal diseases and develops cell-based products for animal health. Overall, ISCO takes a holistic approach to the development of stem cell therapies and cell products. The company places equal emphasis on scientific research and product development for consumer use. ISCO's business model has been highly successful, leading to consistent growth in recent years. Since its founding in 2001, the company has successfully completed multiple rounds of financing and plans to launch more products and therapies in the future. Through a combination of extensive research and development and a successful product range, ISCO has established itself as a leading company in the field of stem cell therapies. With a global presence and a strong position in veterinary medicine, the company will continue to play an important role in researching new therapeutic possibilities.

The expected revenue of International Stem Cell is 7.32 M USD. This figure is based on current financial data and reflects the company's business performance.

The expected profit of International Stem Cell is -5.76 M USD. The net profit reflects the company's profitability after deducting all expenses.

The price-to-earnings ratio (P/E) of International Stem Cell is currently -0.02. The P/E ratio compares the current share price to the earnings per share and helps investors assess the valuation of the International Stem Cell stock.

The price-to-sales ratio (P/S) of International Stem Cell is currently 0.02. The P/S ratio compares the market capitalization to the annual revenue and serves as a valuation metric for the International Stem Cell stock.

The Eulerpool Quality Score for International Stem Cell is 2/10.

The ISIN of International Stem Cell is US4603782016. The ISIN (International Securities Identification Number) is a globally unique identifier for securities.

The ticker of International Stem Cell is ISCO. The ticker symbol is used to trade International Stem Cell shares on the stock exchange.

International Stem Cell paid dividends every year for the past 0 years.

International Stem Cell is assigned to the 'Health' sector.

The dividends of International Stem Cell are distributed in USD.

All fundamentals and in-depth analysis of International Stem Cell

Our stock analysis for International Stem Cell stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of International Stem Cell. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.

International Stem Cell Stock
International Stem Cell Revenue→
International Stem Cell Stock
International Stem Cell Net Income→
International Stem Cell Stock
International Stem Cell P/E→
International Stem Cell Stock
International Stem Cell P/S→
International Stem Cell Stock
International Stem Cell EBIT→
International Stem Cell Stock
International Stem Cell Dividend→
International Stem Cell Stock
International Stem Cell Directors Dealings→
International Stem Cell Stock
International Stem Cell Stocks→
International Stem Cell Stock
International Stem Cell Market capitalization→
International Stem Cell Stock
International Stem Cell Debt→
International Stem Cell Stock
International Stem Cell Liabilities→
International Stem Cell Stock
International Stem Cell Equity→
International Stem Cell Stock
International Stem Cell AAQS→
International Stem Cell Stock
International Stem Cell Employees→
International Stem Cell Stock
International Stem Cell ROE→
International Stem Cell Stock
International Stem Cell ROA→
International Stem Cell Stock
International Stem Cell ROCE→
International Stem Cell Stock
International Stem Cell News→
International Stem Cell Stock
International Stem Cell Analyst Price Targets→

Health Stocks

Internet InfinityIntermedical Care and Lab Hospital PCLInterojo CoInterCureInterpace BiosciencesInterconnect VenturesIntervaccIntensity TherapeuticsIntoCellIntelligent Bio SolutionsIntrasenseIntellia TherapeuticsAll Stocks A–Z →